| 2738071 |
Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties.
Furie, B,
Stafford, DW,
Diuguid, DL,
Liebman, HA,
Rabiet, MJ,
Ware, J,
Kasper, CK,
Furie, BC
|
J Biol Chem |
1989 |
| 2775660 |
Factor IX Cardiff: a variant factor IX protein that shows abnormal activation is caused by an arginine to cysteine substitution at position 145
Giddings, JC,
Bloom, AL,
Peake, IR,
Lillicrap, DP,
Taylor, SA,
Liddell, MB
|
Br. J. Haematol. |
1989 |
| 3461460 |
Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor
Diuguid, DL,
Furie, BC,
Rabiet, MJ,
Furie, B,
Liebman, HA
|
Proc. Natl. Acad. Sci. U.S.A. |
1986 |
| 8295821 |
The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation by factor XIa
Bischoff, R,
Charmantier, JL,
Hartmann, ML,
Roecklin, D,
de la Salle, C,
Ohlmann, P,
Balland, A,
Schuhler, S,
Ravanat, C,
Ebel, C
|
Nouv Rev Fr Hematol |
1993 |
| 2752109 |
Molecular defects of factor IX Chicago-2 (Arg 145----His) and prothrombin Madrid (Arg 271----cys): arginine mutations that preclude zymogen activation
Diuguid, DL,
Furie, BC,
Rabiet, MJ,
Furie, B
|
Blood |
1989 |
| 2162822 |
Mutations in hemophilia Bm occur at the Arg180-Val activation site or in the catalytic domain of factor IX
Reitsma, PH,
Poort, SR,
Mannucci, PM,
van der Linden, IK,
Bertina, RM,
Reinalda-Poot, HH,
Cupers, R
|
J. Biol. Chem. |
1990 |
| 2592373 |
Blood clotting factor IX BM Nagoya. Substitution of arginine 180 by tryptophan and its activation by alpha-chymotrypsin and rat mast cell chymase
Niho, Y,
Suehiro, K,
Saito, H,
Ogata, K,
Takeya, H,
Kawabata, S,
Kamiya, T,
Miyata, T,
Iwanaga, S,
Takamatsu, J
|
J. Biol. Chem. |
1989 |
| 2713493 |
Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo
Lundblad, RL,
Roberts, HR,
McCord, DM,
High, KA,
Huang, MN,
Kasper, CK,
Monroe, DM
|
Blood |
1989 |
| 9169594 |
Modification of the N-terminus of human factor IX by defective propeptide cleavage or acetylation results in a destabilized calcium-induced conformation: effects on phospholipid binding and activation by factor XIa
Van Den Berg, M,
Wojcik, EG,
Poort, SR,
Bertina, RM
|
Biochem. J. |
1997 |
| 2788012 |
Defective propeptide processing and abnormal activation underlie the molecular pathology of factor IX Troed-y-Rhiw
Bloom, AL,
Peake, IR,
Lillicrap, DP,
Liddell, MB
|
Br. J. Haematol. |
1989 |
